Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial

CDK4/6 inhibitors have shown a synergistic effect with anti-HER2 therapy in hormone receptor (HR)-positive and HER2-positive breast cancer (BC). In this phase 2 study (NCT04293276), we aim to evaluate a dual-oral regimen of CDK4/6 inhibitor dalpiciclib combined with HER2 tyrosine kinase inhibitor py...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Min, Niu, Limin, Lv, Huimin, Zhang, Mengwei, Wang, Jing, Liu, Zhenzhen, Chen, Xiuchun, Lu, Zhenduo, Zhang, Chongjian, Zeng, Huiai, Zhao, Shengnan, Feng, Yajing, Sun, Huihui, Li, Huajun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560297/
https://www.ncbi.nlm.nih.gov/pubmed/37805496
http://dx.doi.org/10.1038/s41467-023-41955-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560297/
https://www.ncbi.nlm.nih.gov/pubmed/37805496
http://dx.doi.org/10.1038/s41467-023-41955-7

Ejemplares similares